UCB Ventures
Investment Details
Investor Type
Corporate VC
Asset Class Focus
Venture Capital
Stage Focus
Pre-Seed, Seed, Series A, Series B
Geographical Focus
United States, United Kingdom, Germany, France, Italy, Denmark, Switzerland, Spain, Luxembourg, Ireland, Austria, Netherlands, Portugal, Sweden, Belgium, Norway, Finland, Poland, Czech Republic, Slovakia
Industries Focus
- Healthcare
- Digital Health
- Pharmaceuticals
- Medical Devices
- Diagnostics
- Biotechnology
- Regenerative Medicine
- Oncology
- Neurology
- Infectious Diseases
- Immunology
- Rare Diseases
- Cardiovascular
- Cell and Gene Therapy
- Metabolic Disorders
Investment Size:
100,000 to 1,500,000 USD
Investor Details Founded: 2017
UCB Ventures is a €150 million strategic corporate venture fund established in 2017 to strengthen UCB's ability to create value from novel insights and technologies that can transform the lives of patients suffering from severe diseases. The fund focuses on early-stage investments in innovative therapeutics and technology platforms, particularly in areas adjacent to or beyond UCB's therapeutic focus on neurology, immunology, and musculoskeletal health. UCB Ventures seeks breakthrough innovations in next-generation cell and gene therapy, regenerative medicine, cell and tissue homeostasis, and RNA modulation.
The fund is known for its speed and agility, yet thoughtful and sophisticated approach. UCB Ventures takes an active role in its portfolio companies, contributing expertise in drug discovery, development, and operations. The team works closely with entrepreneurs to bring out the best in their portfolio companies, aiming to deliver impactful therapies to patients.
UCB Ventures has made 18 investments, with its most recent investment on June 11, 2025, when Splice Bio raised an undisclosed amount. The fund has had notable exits, including EsoBiotec, MyHealthTeams, and Syndesi Therapeutics. UCB Ventures is committed to long-term investments, working closely with entrepreneurs to bring out the best in their portfolio companies.
Requirements
- Innovative therapeutics
- Technology platforms
- Early-stage companies
- High-risk, high-reward science
- Breakthrough innovations in life sciences
Contact
[Official Website Hidden]
[LinkedIn Profile Hidden]
[HQ Location Hidden]
[Email Hidden]
Portfolio Companies
- Splice Bio
- EsoBiotec
- MyHealthTeams
- Syndesi Therapeutics
Mentioned In
Claim this Investor
Are you an official representative of UCB Ventures?
Claim this investor to update information, manage your profile, and get a verified seal.
Claim